A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia

被引：0

作者：

Dahir, Kathryn ^{[1
]}

Dunn, Derek ^{[2
]}

Hasan, Jawad ^{[2
]}

Shannon, Amy ^{[2
]}

Pan, Wei-Jian ^{[2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Alexion, AstraZeneca Rare Dis, Boston, MA USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SUN-492

引用

页码：374 / 374

页数：1

共 50 条

[1] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIA
Dahir, K.
Dunn, D.
Mitter, S.
Hasan, J.
Shannon, A.
Pan, W.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S43 - S44
[2] A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia
Dahir, Kathryn
Dunn, Derek
Hasan, Jawad
Shannon, Amy
Pan, Wei-Jian
JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 70 - 70
[3] A PHASE 1, OPEN-LABEL, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1850 IN ADULTS WITH HYPOPHOSPHATASIA
Dahir, K.
Dunn, D.
Mitter, S.
Hasan, J.
Shannon, A.
Pan, W.
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S191 - S192
[4] Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial
Buchtele, Nina
Schwameis, Michael
Schoergenhofer, Christian
Derhaschnig, Ulla
Firbas, Christa
Karch, Rudolf
Nix, Darrell
Schenk, Roman
Jilma, Bernd
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (05) : 979 - 990
[5] A Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Adults with ENPP1 Deficiency
Sabbagh, Yves
Wermers, Robert
Fuhr, Rainard
Schnabel, Dirk
Arnason, Terra
Besancon, Alix
Cizman, Borut
Wenkert, Deborah
Gunter, Kurt
JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 72 - 72
[6] Phase 1/2, Open-Label, Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ701 in Adults with ENPP1 Deficiency
Sabbagh, Yves
Wermers, Robert
Fuhr, Rainard
Schnabel, Dirk
Arnason, Terra
Besancon, Alix
Cizman, Borut
Wenkert, Deborah
Gunter, Kurt
JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 376 - 377
[7] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ENSIFENTRINE IN HEALTHY CHINESE ADULTS: A PHASE 1, OPEN-LABEL, SINGLE AND MULTIPLE DOSE STUDY
Meng, Haijin
Li, Xin
Chen, Charlie
Cheng, Cecilia
Zhang, Ping
Yuan, Chenchen Zhang
CHEST, 2024, 166 (04) : 4758A - 4758A
[8] Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L)
Parsons-Rich, D.
Hua, F.
Li, G.
Kantaridis, C.
Ittman, D. D. P.
Arkin, S.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (05) : 931 - 937
[9] Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study
Bach, Thanh
Galbiati, Shirley
Kennedy, Jessie K.
Deye, Gregory
Nomicos, Effie Y. H.
Codd, Ellen E.
Garcia, Hector H.
Horton, John
Gilman, Robert H.
Gonzalez, Armando E.
Winokur, Patricia
An, Guohua
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
[10] Tormentil for active ulcerative colitis : An open-label, dose-escalating study
Huber, Roman
Ditfurth, Amelie V.
Amann, Frank
Guethlin, Corina
Rostock, Matthias
Trittler, Rainer
Kuemmerer, Klaus
Merfort, Irmgard
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (09) : 834 - 838

← 1 2 3 4 5 →